Clinical trial
Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic…
NCT00045227 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00045227 |
|---|---|
| Title | Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer |
| Official title | A Pilot Trial of Pox Vector PSA Vaccine With Concurrent Docetaxel Versus Pox Vector Vaccine Followed by Docetaxel in Metastatic Androgen Independent Prostate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological, Drug |
| Interventions | recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine, sargramostim, docetaxel |
| Start date | Aug 1, 2002 |
| Completion | Oct 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: